TICKERNERD
Menu
KPTIKPTIHealthcare · Biotechnology

KPTI Stock Forecast: Karyopharm Therapeutics, Inc. Price Predictions for 2026-2027

Last close, 3 Aug 2026
$1.97
+2.60% on the day

The 6 Wall Street analysts covering Karyopharm Therapeutics, Inc. hold a median 12-month price target of $8 — +306.1% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 51 of 100 as at 1 Aug 2026 — in the upper half.

Market cap
$44.6M
Ticker Nerd rank
51 / 100
Median analyst target
$8.00
Analysts covering
6
Total return, dividends reinvested
1W
−72.2%
1M
−79.5%
YTD
−73.2%
1Y
−49.9%
From 52W high
−81.5%
From 52W low
+2.6%
$2
$11
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

KPTI stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Karyopharm Therapeutics, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 1 Aug 2026
51 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Accruals
94
Size
83
Value
73
Growth
67
Momentum
44
Quality
43
Revisions
32
Volatility
27
Issuance
5

Accruals (94): Reported profit is backed by cash, and the company is not expanding recklessly.

Issuance (5): The company has been issuing shares or taking on financing, diluting existing holders.

The rank is the raw material. Whether the rules would actually own Karyopharm Therapeutics, Inc. — and when they’d sell — is the membership.

Wall Street

KPTI stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on KPTI, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$2$4$6$8$10$12Oct 25Jan 26Apr 26Jul 26KPTIHigh $11.00Median $8.00Low $7.00

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

What Wall Street says6 analysts
4 Buy2 Hold0 Sell
Low $7.00Median $8.00High $11.00

The green dot is the last close — the median target sits +306.1% from it.

Recent analyst actionsNewest first

Of the 20 most recent actions, 1 moved their price target up and 2 moved it down.

DateFirmActionRatingTarget
31 July 2026HC Wainwright & Co.DowngradeNeutral$13 → $3.00
31 July 2026Piper SandlerMaintainsOverweight$16 → $7.00
6 May 2026HC Wainwright & Co.MaintainsBuy—
6 May 2026HC Wainwright & Co.MaintainsBuy$8.00 → $13
27 Apr 2026Piper SandlerReiteratesOverweight—
30 Mar 2026Piper SandlerReiteratesOverweight—
25 Mar 2026BairdMaintainsOutperform—
25 Mar 2026HC Wainwright & Co.MaintainsBuy—
10 Mar 2026Rodman & RenshawInitiatesBuy—
18 Feb 2026HC Wainwright & Co.ReiteratesBuy—
5 Feb 2026Cantor FitzgeraldInitiatesOverweight—
4 Nov 2025RBC CapitalMaintainsOutperform—
13 Oct 2025HC Wainwright & Co.UpgradeBuy—
9 Oct 2025BairdMaintainsOutperform—
9 Oct 2025Piper SandlerReiteratesOverweight—
12 Aug 2025BairdMaintainsOutperform—
16 July 2025HC Wainwright & Co.DowngradeNeutral—
11 July 2025HC Wainwright & Co.AssumesBuy$27
13 May 2025BairdMaintainsOutperform—
13 May 2025BarclaysMaintainsOverweight—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Estimates

KPTI analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
Analysts raising
1
Analysts cutting
0
Fundamentals

Karyopharm Therapeutics, Inc. (KPTI) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
−0.1×

Cheaper than 76% of US stocks

Price / sales
0.3×

Cheaper than 89% of US stocks

Price / book
−0.2×

Cheaper than 93% of US stocks

EV / EBITDA
−3.0×

Cheaper than 75% of US stocks

Growth & margins
Revenue growth (YoY)
16.8%

Higher than 68% of US stocks

Earnings growth (YoY)
16.8%

Higher than 58% of US stocks

Gross margin
96.2%

Higher than 99% of US stocks

Operating margin
−76.3%

Higher than 15% of US stocks

Net margin
−129.0%

Higher than 4% of US stocks

Returns & dividend
Return on equity
66.9%

Higher than 94% of US stocks

Return on assets
−40.6%

Higher than 10% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Peers

KPTI vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
KPTIKaryopharm Therapeutics, Inc.$44.6M
51
RNXTRenovoRx, Inc.$43.2M
32
EXOZeXoZymes, Inc.$43.2M
14
MGXMetagenomi Therapeutics, Inc.$44.7M
27
IBOImpact BioMedical, Inc.$45.0M
24
TVGNTevogen, Inc.$45.2M
15
MCRBSeres Therapeutics, Inc.$46.3M
64
Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. KPTI appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

News

Latest KPTI news & analysis

Karyopharm Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

PRNewsWire · 3 Aug 2026neutral

Karyopharm Therapeutics announced that it granted 333 restricted stock units (RSUs) to one newly-hired employee. The grant was reported under Nasdaq Listing Rule 5635(c)(4), which covers equity inducement awards for new employees.

Why it matters — KPTI watchers would care because the announcement reflects the company's equity-compensation activity for new hires, a routine corporate disclosure tracked by shareholders and Nasdaq-listed issuers.

Karyopharm Plans to Submit sNDA for Selinexor Plus Ruxolitinib in Myelofibrosis Under Accelerated Approval Pathway

PRNewsWire · 30 July 2026positive

Karyopharm Therapeutics announced plans to submit a supplemental New Drug Application (sNDA) to the FDA in August 2026 seeking accelerated approval of selinexor in combination with ruxolitinib for patients with myelofibrosis, and will request Priority Review.

Why it matters — The submission could lead to selinexor becoming the first approved combination therapy for myelofibrosis, representing a potential expansion of Karyopharm's commercial product into a new indication.

Karyopharm Announces Topline Results from Phase 3 XPORT-EC-042 Trial in Endometrial Cancer

PRNewsWire · 30 July 2026negative

Karyopharm announced that its Phase 3 XPORT-EC-042 trial evaluating selinexor as maintenance therapy for TP53 wild-type advanced or recurrent endometrial cancer did not meet the primary endpoint of progression-free survival, though a trend favoring the selinexor arm was observed. The company plans to prioritize resources on its myelofibrosis and multiple myeloma programs and reduce planned investment in endometrial cancer.

Why it matters — A Phase 3 miss in endometrial cancer narrows KPTI's pipeline focus and reduces the potential commercial opportunity for selinexor beyond its existing indications.

FAQ

Frequently asked questions about KPTI stock

What is the KPTI stock price forecast for 2026-2027?

The 6 Wall Street analysts covering Karyopharm Therapeutics, Inc. have a median 12-month price target of $8, with estimates ranging from $7 to $11. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is KPTI stock a buy right now?

Of the 6 analysts covering Karyopharm Therapeutics, Inc., 4 rate it a Buy, 2 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Karyopharm Therapeutics, Inc. 51 out of 100 across roughly 4,600 US stocks as at 1 Aug 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank KPTI?

As at 1 Aug 2026, Karyopharm Therapeutics, Inc. ranks 51 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Accruals (94 of 100).

Will KPTI stock go up?

No one can know that. What the data says: the median 12-month target from 6 analysts implies +306.1% from the last close, and Ticker Nerd's factor model ranks Karyopharm Therapeutics, Inc. 51 out of 100 as at 1 Aug 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the KPTI stock forecast for 2030?

No analyst covering Karyopharm Therapeutics, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for KPTI are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $7 to $11 over the next 12 months.

How has KPTI stock performed over the past year?

Karyopharm Therapeutics, Inc. returned -49.9% over the 12 months to 3 Aug 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Karyopharm Therapeutics, Inc. do?

Karyopharm Therapeutics Inc. is a commercial-stage biopharmaceutical company specializing in the discovery, development, and commercialization of innovative cancer therapies.

What is the latest news on KPTI?

The most recent item we track (PRNewsWire, 3 Aug 2026): "Karyopharm Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)". Karyopharm Therapeutics announced that it granted 333 restricted stock units (RSUs) to one newly-hired employee. The grant was reported under Nasdaq Listing Rule 5635(c)(4), which covers equity inducement awards for new employees.

Company

About Karyopharm Therapeutics, Inc.

Karyopharm Therapeutics Inc. is a commercial-stage biopharmaceutical company specializing in the discovery, development, and commercialization of innovative cancer therapies. The company focuses on nuclear export inhibition, having developed small-molecule compounds that target exportin 1 (XPO1), a protein involved in intracellular communication between the nucleus and cytoplasm. The company's lead therapeutic product is XPOVIO (selinexor), which is approved in the United States for treating multiple hematologic malignancies, including multiple myeloma in combination with established therapies and relapsed or refractory diffuse large B-cell lymphoma as a monotherapy. Karyopharm operates primarily in the healthcare and biotechnology sectors, deriving revenue from the United States market. Headquartered in Newton, Massachusetts, the company remains dedicated to advancing novel cancer treatment options through its specialized platform targeting nuclear export mechanisms.

CEO Mr. Richard A. Paulson M.B.A. · 228 employees · United States · https://www.karyopharm.com